Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields (NCT04469075)
The PROTECT Study: A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy With Clindamycin and Triamcinolone in Glioblastoma Patients Treated With Tumor Treating Fields
🩺 Plain-English Summary (8th-Grade Level)
The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (8 items).
Location: Northwestern University — Evanston, Illinois
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Known history of allergy to any ingredient of the study agents
- Preexisting scalp disorders such as psoriasis or dermatitis that, in the opinion of the investigator, will affect the grading of skin adverse events, confirmed by enrolling institution.
- Use of concurrent topical therapy to the scalp for another dermatologic condition
- Active, uncontrolled infection requiring systemic or oral antibiotic therapy within 14 days of enrollment
- Use of greater than 4 mg dexamethasone a day within 14 days of enrollment
- Malignant glioma
- Pregnant Women
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (8 Sites)
- Northwestern University — Evanston, Illinois
- Tufts Medical Center — Boston, Massachusetts
- Washington University School of Medicine — St Louis, Missouri
- Hackensack Meridian Health — Hackensack, New Jersey
- Memorial Sloan Kettering Cancer Center Suffolk - Hauppauge (All Protocol Activities) — Hauppauge, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Columbia University — New York, New York
- University of Cincinnati Medical Center — Cincinnati, Ohio
📞 Contact the Study Coordinator
Phone: (855) 692-6482
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Glioblastoma
- Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue — Miami, Florida
- Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma — Milwaukee, Wisconsin
- A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. — New York, New York
- Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma — St Louis, Missouri
- A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors — San Francisco, California
- Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma — Philadelphia, Pennsylvania
Explore by condition: All Glioblastoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.